Atlas Arteria rejects IFM Investors takeover proposal
The board of Atlas Arteria (ASX:ALX) has urged its retail shareholders to reject a financing and restructure proposal from IFM Investors for the Chicago Skyway toll road.

Finance journalist at Grafa with years of experience covering Asia-Pacific financial markets at S&P Global, Mortgage Ezy, and GMA Network.
The board of Atlas Arteria (ASX:ALX) has urged its retail shareholders to reject a financing and restructure proposal from IFM Investors for the Chicago Skyway toll road.
The International Monetary Fund (IMF) said tokenisation could transform financial markets by moving assets, settlement and recordkeeping onto shared digital ledgers, reducing settlement times from days to near-instant transactions.
NSW regulator IPART proposes a 20% cut to PEXA (ASX:PXA) regulated revenue, risking an estimated $70 million reduction by FY28.
Federal Bureau of Investigation Director Kash Patel amended his financial disclosure to report an investment in Strategy worth between US$100,001 and US$250,000 after failing to disclose the purchase within the timeframe required under the STOCK Act.
Catalyst Metals (ASX:CYL) reported record gold production from its flagship Plutonic Gold Belt asset in Western Australia.
TradingView has integrated live market data from Hyperliquid, associated with Hyperliquid (CRYPTO:HYPE), and Trade[XYZ], allowing users to monitor cryptocurrency, equity, commodity, foreign exchange and pre-IPO perpetual markets from a single platform.
Tourism Holdings (ASX:THL) has executed a confidentiality agreement to grant due diligence access to a consortium bidding.
Super Micro Computer (NASDAQ:SMCI) said two employees at its Taiwan unit were detained by prosecutors in connection with an investigation into alleged illegal export of AI servers containing Nvidia (NASDAQ:NVDA) chips.
Revolution Medicines (NASDAQ:RVMD) reported Phase 1/2 data showing up to an 82% response rate for zoldonrasib combinations.
Polyrizon (NASDAQ:PLRZ) said it has completed the biocompatibility evaluation program for its NASARIX™ Allergy Blocker nasal spray.